Phase 3 Ankylosing Spondylitis Trial, Recruiting (NCT07172360)

Phase 3 Ankylosing Spondylitis Trial, Recruiting NCT07172360 Sponsor: Jiangsu vcare pharmaceutical technology co., LTD Condition: Ankylosing Spondylitis

Printed from Voxsanity (voxsanity.com.au) — NCT07172360 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Ankylosing Spondylitis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You understand what the trial involves and are willing to sign a consent form agreeing to take part and follow the study rules
You are between 18 and 70 years old (including those ages exactly) at the time of signing the consent form, and any gender is welcome
You have been diagnosed with Ankylosing Spondylitis (a type of inflammatory arthritis mainly affecting the spine) based on a specific set of recognised medical criteria from 1984 called the New York Revised Criteria

Who may not be able to join:

You have a known or suspected allergy to the study drug (VC005), similar drugs, or any of their ingredients
You have had an organ transplant in the past and currently need to take ongoing medicines to suppress your immune system
The doctor running the trial decides, for any reason, that the trial would not be appropriate for you (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Zhanguo Li, Peking University People's Hospital

Phone: 15358160458

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07172360

Sponsor: Jiangsu vcare pharmaceutical technology co., LTD

Phase: Phase 3

Status: Recruiting

Condition: Ankylosing Spondylitis

Trial contact: 15358160458

More information: https://clinicaltrials.gov/study/NCT07172360

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You understand what the trial involves and are willing to sign a consent form agreeing to take part and follow the study rules
You are between 18 and 70 years old (including those ages exactly) at the time of signing the consent form, and any gender is welcome
You have been diagnosed with Ankylosing Spondylitis (a type of inflammatory arthritis mainly affecting the spine) based on a specific set of recognised medical criteria from 1984 called the New York Revised Criteria

Who may not be able to join:

You have a known or suspected allergy to the study drug (VC005), similar drugs, or any of their ingredients
You have had an organ transplant in the past and currently need to take ongoing medicines to suppress your immune system
The doctor running the trial decides, for any reason, that the trial would not be appropriate for you (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 3

Sponsor

Jiangsu vcare pharmaceutical technology co., LTD

Registry

ClinicalTrials.gov

Start date

26 December 2025

Est. completion

30 August 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Percentage of patients achieving an Assessment of disease activity (signs and symptoms) in ankylosing spondylitis 20% improvement (ASAS20) in response at week 12 of treatment.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov